Skip to main content
CIZZLE BIOTECHNOLOGY HOLDINGS PLC logo

CIZZLE BIOTECHNOLOGY HOLDINGS PLC — Investor Relations & Filings

Ticker · CIZ ISIN · GB00BNG2VN02 LEI · 213800G3OS3SA2J1Y358 IL Professional, scientific and technical activities
Open in API
Filings indexed 305 across all filing types
Latest filing 2022-09-23 Regulatory Filings
Country GB United Kingdom
Listing IL CIZ

About CIZZLE BIOTECHNOLOGY HOLDINGS PLC

https://cizzlebiotechnology.com/

Cizzle Biotechnology Holdings PLC is a cancer diagnostics developer focused on the early detection of lung cancer. The company is advancing a non-invasive, cost-effective blood test designed to identify lung cancer at its earliest stages, often before symptoms appear. The test utilizes a proprietary CIZ1B biomarker and an advanced immunoassay. Its primary goal is to improve patient outcomes by enabling swift, curative medical intervention. The technology aims to streamline the diagnostic pathway, reduce reliance on CT scans which can have high false-positive rates, and eliminate unnecessary invasive follow-up procedures. The company, a spin-out from the University of York, is conducting clinical trials to support global regulatory approval and adoption of its technology.

Recent filings

Filing Released Lang Actions
Cizzle Biotechnology Holdings plc - Single prospectus
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "prospectus relating to Cizzle Biotechnology Holdings plc dated 21 September 2022". It details the approval process by the Financial Conduct Authority (FCA) under the Prospectus Regulation, discusses the proposed subscription of new ordinary shares, and outlines the application for admission to the Official List and London Stock Exchange. A prospectus is a key document used when offering securities to the public, often associated with fundraising or listing activities. This aligns most closely with the 'Capital/Financing Update' (CAP) category, as it is fundamentally about raising capital through a share offering and subsequent listing/admission. While a prospectus contains extensive information, its primary purpose here is the financing activity described (Proposed Subscription of 35,666,665 New Ordinary Shares). It is not a standard Annual Report (10-K), Interim Report (IR), or simple Earnings Release (ER).
2022-09-23 English
Prospectus in relation to the Proposed Subscription of 35,666,665 New Ordinary Shares at 1.5p per share.
Regulatory Filings Classification · 1% confidence The document explicitly identifies itself as a "Prospectus" dated 21 September 2022, prepared in accordance with the Prospectus Regulation and approved by the FCA. It details a proposed subscription of new ordinary shares and their intended admission to the Official List and London Stock Exchange. A prospectus is a key document used for offering securities to the public, which aligns closely with the purpose of a Capital/Financing Update (CAP) or a document related to a major corporate action involving share issuance. However, given the comprehensive nature, regulatory approval context (FCA approval, Prospectus Regulation), and the focus on raising capital through a share offering, this document is fundamentally a document soliciting investment based on detailed company information, risks, and financial structure. While it involves capital changes (SHA), the primary function of a Prospectus in this context is to facilitate the offering/listing, which is best captured by the 'Capital/Financing Update' (CAP) category, as it details the terms of the subscription and admission. It is not a standard 10-K, AR, or ER. Since it details the terms of a share issue/subscription, CAP is the most appropriate fit over SHA (which is usually a simpler announcement of a change) or RNS (which is a fallback).
2022-09-21 English
Subscription, Facility & Publication of Prospectus
Regulatory Filings Classification · 1% confidence The document is an official announcement disseminated via an RNS Number (1633A) on September 21, 2022. The text explicitly mentions key corporate actions: a £500,000 Subscription, securing a £500,000 Facility, and crucially, the 'Publication of a Prospectus'. It details the terms of the share issuance (Subscription Shares, Commission Shares, Facility Shares) and provides an expected timetable for Admission to the London Stock Exchange. While it announces the publication of a Prospectus, the primary function of this specific document is to serve as a regulatory disclosure regarding fundraising and capital changes, disseminated through the Regulatory Information Service (RNS). Since it details the mechanics of a capital raise (£500,000 Subscription and a £500,000 Facility) and the associated share issuances, it strongly aligns with the 'Capital/Financing Update' (CAP). However, because it is distributed via RNS and announces multiple related events including the prospectus publication, the most encompassing and appropriate regulatory category for this type of formal, market-moving disclosure distributed via an RIS is 'Regulatory Filings' (RNS), which serves as the general category for such announcements that are not strictly a 10-K, ER, or IR. Given the strong emphasis on fundraising and share issuance, CAP is also highly relevant, but RNS is the mechanism of delivery and a common classification for these types of announcements. Since the document is substantial (15,873 chars) and contains the full details of the financing, it is the filing itself, not just an announcement of a report. I will classify it as CAP due to the core subject matter being capital raising, which is more specific than the general RNS fallback.
2022-09-21 English
Arcadia Clinical Trial Results Published
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 4617W' and contains a date stamp typical of regulatory news services. The content announces that clinical trial results for a drug (AZD1656) have been published in a third-party journal ('Lancet eClinicalMedicine'). This is an announcement about an external event/publication, not the full financial report (10-K, IR) or the presentation itself (IP, AGM-R). Since it is a formal announcement disseminated via RNS (Regulatory News Service) regarding company developments, and it doesn't fit neatly into specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (CAP), the most appropriate classification is the general regulatory announcement fallback category, RNS.
2022-08-18 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1947 characters) and contains the header 'RNS Number : 6168V'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This is a general regulatory announcement that does not fit the specific categories like ER, 10-K, or DIV. Since it is a standard, brief regulatory notification provided via the RNS service, the most appropriate classification is the general Regulatory Filings category.
2022-08-10 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 6155V' and is dated August 10, 2022. The content discusses a 'Price Monitoring Extension' for a security on the London Stock Exchange, which is a standard operational announcement related to trading mechanisms. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement that does not fit into the specific categories like 10-K, ER, or DIV. Given its nature as a routine, non-specific regulatory update disseminated via the RNS system, the most appropriate classification is Regulatory Filings (RNS). The document is short and is an announcement itself, not a detailed report.
2022-08-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.